Sponsored By

J&J Develops Contacts to Address Digital Eye Strain

The New Brunswick, NJ-based company revealed the products during the 125th Annual AOA Congress and 54th Annual AOSA Conference: Optometry’s Meeting.

MDDI Staff

June 20, 2022

2 Min Read
2A7R4T6.jpg
Image courtesy of Quality Stock / Alamy Stock Photo

One of the most common forms of eye strain now comes from looking at the screen for too long. Johnson & Johnson has developed products that will address eye fatigue.

The New Brunswick, NJ-based said it received clearance, Health Canada approval and completed CE Mark activities for its latest contact lens innovation, Acuvue Oasys MAX 1-Day and Acuvue Oasys Max 1-Day Multifocal.

The announcement came during the 125th Annual AOA Congress and 54th Annual AOSA Conference: Optometry’s Meeting.

“Our lives have evolved significantly over the past few years creating increased demands on our eyes,” said Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision. As pioneers in eye health, we’re leading with high science and deep clinical expertise to innovate for those moments that matter. ACUVUE OASYS MAX 1-Day is the latest in our long heritage of leading-edge innovation and we look forward to bringing this solution for patients experiencing ever-demanding lifestyles and environments.”

The new contact lenses were developed to provide all day comfort and visual clarity, amidst feedback from eye care professionals and patients that today’s modern lifestyles, long hours and increased use of digital devices are taking a toll on eye comfort. A recent survey found the majority (71%) of eye care professionals are seeing patients who are experiencing eye discomfort related to increased screen-time, with young contact lens wearers spending an average of 9 hours per day in front of a screen, causing them to blink less and experience more dryness and eye fatigue.

Johnson & Johnson has been expanding the use of contact lens for the past few years. The company took contact lens beyond traditional use when it won approval from the Japanese Ministry of Health, Labour and Welfare for a lens that provides vision correction and Ketotifen, an antihistamine drug to help relieve symptoms for people experiencing itchy allergy eyes.

The company won FDA approval for the lens earlier this year.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like